C Michael Gibson/Baim Institute
Feb 7, 2026, 14:25
C Michael Gibson: Asundexian Reduces Ischemic Stroke Without Increasing Bleeding Risk
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Among patients with non-cardioembolic ischemic stroke or high-risk TIA treated with antiplatelet therapy, asundexian 50 mg reduced the occurrence of ischemic stroke (csHR 0.74; 95% CI, 0.65 to 0.84; p<0.001).
The difference between the treatment arms began early and continued throughout the treatment period.
A consistent effect was seen in subgroups.
Asundexian was associated with a reduction in disabling or fatal stroke (mRS ≥ 3)
Asundexian was not associated with an increase in bleeding Including ISTH major, CRNM, minor or intracranial bleeding.”
Stay updated with Hemostasis Today.
-
Mar 11, 2026, 14:26Cathy Harrison: Hemophilia Nurses Advocating for People Living With Bleeding Disorders
-
Mar 11, 2026, 13:47Carlos Andrés Vergara Sánchez: AI-Driven CCTA Plaque Quantification for Better ASCVD Risk Assessment
-
Mar 11, 2026, 13:44Scott Cameron: Metformin, Aspirin, and Sex-Specific Effects in Abdominal Aortic Aneurysm Growth
-
Mar 11, 2026, 13:35Erwin Loh: Can Fiber-Rich Foods Help Reduce Heart Disease Risk in Night Shift Workers?
-
Mar 11, 2026, 13:33Tareq Abadl: Differentiating Cold Agglutination from Hemolysis
-
Mar 11, 2026, 13:13Louise St Germain Bannon: Celebrating Cary Clark’s 25 Years of Dedication to the ISTH Community
-
Mar 11, 2026, 13:04Philip Wenzel: The Role of MyD88 in the Inflammatory Transition from Hypertension to Heart Failure
-
Mar 11, 2026, 12:58Santagata Davide: How Biological Sex Influences Thrombotic Risk in Patients with Cancer?
-
Mar 10, 2026, 14:33Eugene Tang: A Look at What’s Happening in Life After Stroke Research Across Europe at ELASF 2026